These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26385753)

  • 1. Biologic-associated infections in pediatric rheumatology.
    Horneff G
    Curr Rheumatol Rep; 2015 Nov; 17(11):66. PubMed ID: 26385753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
    Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
    Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
    Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
    Horneff G
    Expert Opin Drug Saf; 2015 Jul; 14(7):1111-26. PubMed ID: 26084637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting.
    Brunelli JB; Schmidt AR; Sallum AME; Goldenstein-Schainberg C; Bonfá E; Silva CA; Aikawa NE
    Mod Rheumatol; 2018 Mar; 28(2):264-270. PubMed ID: 28949278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
    Diener C; Horneff G
    Expert Opin Drug Saf; 2019 Aug; 18(8):719-732. PubMed ID: 31204508
    [No Abstract]   [Full Text] [Related]  

  • 9. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
    Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
    Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
    Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
    Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.
    Cabrera N; Lega JC; Kassai B; Wouters C; Kondi A; Cannizzaro E; Woerner A; Chausset A; Roethlisberger S; Jeanneret C; Aeschlimann F; Malik S; Duquesne A; Kaiser D; Higel L; Maes A; Berthet G; Hentgen V; Kone-Paut I; Belot A; Hofer M
    Joint Bone Spine; 2019 May; 86(3):343-350. PubMed ID: 30201476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I; Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile Idiopathic Arthritis.
    Barut K; Adrovic A; Şahin S; Kasapçopur Ö
    Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
    Nimmrich S; Horneff G
    Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
    Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
    Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
    Kearsley-Fleet L; Davies R; Baildam E; Beresford MW; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2016 Sep; 55(9):1556-65. PubMed ID: 26732349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis.
    Lahiri M; Dixon WG
    Best Pract Res Clin Rheumatol; 2015 Apr; 29(2):290-305. PubMed ID: 26362745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.